Literature DB >> 25526701

Efficient cell-specific uptake of binding proteins into the cytoplasm through engineered modular transport systems.

Wouter P R Verdurmen1, Manuel Luginbühl2, Annemarie Honegger3, Andreas Plückthun4.   

Abstract

Through advances in protein scaffold engineering and selection technologies, highly specific binding proteins, which fold under reducing conditions, can be generated against virtually all targets. Despite tremendous therapeutic opportunities, intracellular applications are hindered by difficulties associated with achieving cytosolic delivery, compounded by even correctly measuring it. Here, we addressed cytosolic delivery systematically through the development of a biotin ligase-based assay that objectively quantifies cytosolic delivery in a generic fashion. We developed modular transport systems that consist of a designed ankyrin repeat protein (DARPin) for receptor targeting and a different DARPin for intracellular recognition and a bacterial toxin-derived component for cytosolic translocation. We show that both anthrax pores and the translocation domain of Pseudomonas exotoxin A (ETA) efficiently deliver DARPins into the cytosol. We found that the cargo must not exceed a threshold thermodynamic stability for anthrax pores, which can be addressed by engineering, while the ETA pathway does not appear to have this restriction.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anthrax toxin; Biotin ligase; Cytoplasmic delivery; Designed ankyrin repeat protein; Protein engineering; Pseudomonas exotoxin A

Mesh:

Substances:

Year:  2014        PMID: 25526701     DOI: 10.1016/j.jconrel.2014.12.019

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   11.467


  31 in total

1.  Quantitative measurement of cytosolic penetration using the chloroalkane penetration assay.

Authors:  Kirsten Deprey; Joshua A Kritzer
Journal:  Methods Enzymol       Date:  2020-04-20       Impact factor: 1.600

2.  Solid tumor therapy by selectively targeting stromal endothelial cells.

Authors:  Shihui Liu; Jie Liu; Qian Ma; Liu Cao; Rasem J Fattah; Zuxi Yu; Thomas H Bugge; Toren Finkel; Stephen H Leppla
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-29       Impact factor: 11.205

3.  Single-molecule spectroscopy of protein conformational dynamics in live eukaryotic cells.

Authors:  Iwo König; Arash Zarrine-Afsar; Mikayel Aznauryan; Andrea Soranno; Bengt Wunderlich; Fabian Dingfelder; Jakob C Stüber; Andreas Plückthun; Daniel Nettels; Benjamin Schuler
Journal:  Nat Methods       Date:  2015-07-06       Impact factor: 28.547

4.  Bismaleimide cross-linked anthrax toxin forms functional octamers with high specificity in tumor targeting.

Authors:  Elyse S Fischer; Warren A Campbell; Shihui Liu; Rodolfo Ghirlando; Rasem J Fattah; Thomas H Bugge; Stephen H Leppla
Journal:  Protein Sci       Date:  2019-04-17       Impact factor: 6.725

5.  Enhancement of hERG channel activity by scFv antibody fragments targeted to the PAS domain.

Authors:  Carol A Harley; Greg Starek; David K Jones; Andreia S Fernandes; Gail A Robertson; João H Morais-Cabral
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-11       Impact factor: 11.205

6.  Antibody Engineering & Therapeutics, the annual meeting of The Antibody Society December 7-10, 2015, San Diego, CA, USA.

Authors:  Matthias Pauthner; Jenny Yeung; Chris Ullman; Joost Bakker; Thierry Wurch; Janice M Reichert; Fridtjof Lund-Johansen; Andrew R M Bradbury; Paul J Carter; Joost P M Melis
Journal:  MAbs       Date:  2016       Impact factor: 5.857

Review 7.  Next generation antibody drugs: pursuit of the 'high-hanging fruit'.

Authors:  Paul J Carter; Greg A Lazar
Journal:  Nat Rev Drug Discov       Date:  2017-12-01       Impact factor: 84.694

Review 8.  Emerging Strategies for Developing Next-Generation Protein Therapeutics for Cancer Treatment.

Authors:  James R Kintzing; Maria V Filsinger Interrante; Jennifer R Cochran
Journal:  Trends Pharmacol Sci       Date:  2016-11-09       Impact factor: 14.819

9.  Selective targeting of metastatic ovarian cancer using an engineered anthrax prodrug activated by membrane-anchored serine proteases.

Authors:  Nadire Duru; Nisha R Pawar; Erik W Martin; Marguerite S Buzza; Gregory D Conway; Rena G Lapidus; Shihui Liu; Jocelyn Reader; Gautam G Rao; Dana M Roque; Stephen H Leppla; Toni M Antalis
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-08       Impact factor: 12.779

10.  A Hybrid In Silico and Tumor-on-a-Chip Approach to Model Targeted Protein Behavior in 3D Microenvironments.

Authors:  Valentina Palacio-Castañeda; Simon Dumas; Philipp Albrecht; Thijmen J Wijgers; Stéphanie Descroix; Wouter P R Verdurmen
Journal:  Cancers (Basel)       Date:  2021-05-18       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.